Back to search
Juvenile Idiopathic Arthritis (JIA)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Juvenile Idiopathic Arthritis (JIA) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Juvenile Idiopathic Arthritis (JIA) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic…
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for…
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants wi…
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juve…
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 1…
Juvenile Idiopathic Arthritis (JIA) is a chronic autoimmune condition starting before age 16, often leading to fatigue, joint stiffness, and decreased physical…
Children and parents often experience uncertainty and stress when juvenile idiopathic arthritis (JIA) is first diagnosed, which creates a need for structured su…